文献速递血栓与止血

低剂量阿哌沙班作为癌症患者静脉血栓栓塞症二级预防——30个月随访

Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up.
PubMed 文献 · J Thromb Haemost · 2022-02-20

该单臂干预临床试验纳入298例癌症合并静脉血栓栓塞症患者,先接受足量阿哌沙班5 mg每日两次治疗6个月,其中196例活动性癌症患者继续接受阿哌沙班2.5 mg每日两次治疗30个月,评估复发VTE、大出血和临床相关非大出血,结论认为足量治疗6个月后减量至2.5 mg每日两次似乎安全。

要点

  • 足量阿哌沙班治疗6个月后减至2.5 mg每日两次,30个月随访中复发VTE发生14例(7.6%,95%CI 4.0%-11.7%)。
  • 低剂量阶段大出血发生6例(3.1%,95%CI 1.1%-6.5%),临床相关非大出血16例(8.1%,95%CI 4.7%-12.8%)。
  • 7-12个月低剂量阿哌沙班期间复发VTE发生率每患者月1.0%(95%CI 0.5-1.9),大出血发生率0.3%(95%CI 0.1-1.0)。

核心结论

  • 足量阿哌沙班治疗6个月后将剂量减至2.5 mg每日两次似乎安全。
  • 治疗12个月后复发VTE和大出血的发生率仍然较低。

研究设计与样本

  • 单臂干预临床试验,纳入298例癌症合并任何类型VTE的患者。
  • 所有患者先接受足量阿哌沙班5 mg每日两次治疗6个月。
  • 6个月治疗后仍有活动性癌症的196例患者继续接受阿哌沙班2.5 mg每日两次治疗30个月。

主要发现

  • 低剂量阿哌沙班30个月治疗期间,14例(7.6%,95%CI 4.0%-11.7%)发生复发VTE。
  • 大出血6例(3.1%,95%CI 1.1%-6.5%),临床相关非大出血16例(8.1%,95%CI 4.7%-12.8%)。
  • 2-6个月足量阿哌沙班期间复发VTE每患者月发生率为0.8%(95%CI 0.41-1.6),7-12个月低剂量期间为1.0%(95%CI 0.5-1.9)。
  • 2-6个月大出血每患者月发生率为1.1%(95%CI 0.6-2.0),7-12个月为0.3%(95%CI 0.1-1.0)。
  • 12至36个月期间复发VTE和大出血的发生率仍然较低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are no data on the effect of low-dose anticoagulation as secondary prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy and safety of low-dose apixaban for 30 months, after initial 6 months of full-dose treatment. METHODS: We included 298 patients with cancer and any type of VTE in a single arm interventional clinical trial. All patients were treated with full-dose apixaban (5 mg twice daily) for 6 months. Total 196 patients with active cancer after 6 months treatment continued with apixaban 2.5 mg twice daily for another 30 months. The main endpoints were recurrent VTE, major bleeding and clinically relevant non-major bleeding. RESULTS: During the 30 months of treatment with low-dose apixaban 14 (7.6%; 95% confidence interval (CI) 4.0%-11.7%) patients experienced recurrent VTE, six (3.1%; 95% CI 1.1%-6.5%) experienced major bleeding and 16 (8.1%, 95% CI: 4.7%-12.8%) experienced clinically relevant non-major bleeding. The incidence rate per person month of recurrent VTE was 0.8% (95% CI 0.41-1.6) at 2-6 months with full-dose apixaban, and 1.0% (95% CI 0.5-1.9) at 7-12 months with low-dose apixaban. The incidence rate of major bleeding was 1.1% (95% CI 0.6-2.0) at 2-6 months, and 0.3% (95% CI 0.1-1.0) at 7-12 months. Between 12 and 36 months the incidence rate of recurrent VTE and major bleedings remained low. CONCLUSION: Dose reduction of apixaban to 2.5 mg twice daily seems safe after 6 months of full-dose treatment. After 12 months the incidence rate of recurrent VTE and major bleeding remained low.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Larsen TL, Garresori H, Brekke J, et al. Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up. J Thromb Haemost. 2022. PMID: 35114046. doi:10.1111/jth.15666

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。